Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

• Egile Nagusiak: Shaymaa E. Kassab (Egilea), Samar Mowafy (Egilea), Aya M. Alserw (Egilea), Joustin A. Seliem (Egilea), Shahenda M. El-Naggar (Egilea), Nesreen N. Omar (Egilea), Mohamed M. Awad (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective HDAC6 inhibitors is important to minimise the side effects of pan inhibition. Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity a...